Pharmacokinetics of haloperidol

Pharmacokinetics of haloperidol - Pharmacokinetics of haloperidol

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON39461

Enrollment

Registered

2012-01-11

Start date

2012-01-30

Completion date

Unknown

Last updated

2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

farmacokinetiek van een geneesmiddel/antipsychoticum pharmacokinetics

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: age >64 years elective operation with spinal anesthesia elevated risk to develop a delirium and prescription of haloperidol during five days pre-operative in a dose of 1mg/dag as regular care mentally competent informed consent

Exclusion criteria

Exclusion criteria: none

Design outcomes

Primary

Measure	Time frame
concentration haloperidol in serum and liquor Farmacogenetic polymorfisms of the cytochroom P450 enzym CYP2D6	—

Secondary

Measure	Time frame
age, gender, race, smoking, medication use	—

Countries

Netherlands

Outcome results